- Home
- NAMS vs PLXS Comparison
NAMS vs PLXS Comparison
Compare NAMS & PLXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAMS
- PLXS
- Stock Information
- Founded
- NAMS 2019
- PLXS 1979
- Country
- NAMS Netherlands
- PLXS United States
- Employees
- NAMS N/A
- PLXS N/A
- Industry
- NAMS Biotechnology: Pharmaceutical Preparations
- PLXS Electrical Products
- Sector
- NAMS Health Care
- PLXS Technology
- Exchange
- NAMS Nasdaq
- PLXS Nasdaq
- Market Cap
- NAMS 3.1B
- PLXS 3.7B
- IPO Year
- NAMS N/A
- PLXS 1986
- Fundamental
- Price
- NAMS $40.29
- PLXS $144.09
- Analyst Decision
- NAMS Strong Buy
- PLXS Buy
- Analyst Count
- NAMS 10
- PLXS 4
- Target Price
- NAMS $44.80
- PLXS $157.50
- AVG Volume (30 Days)
- NAMS 1.0M
- PLXS 163.7K
- Earning Date
- NAMS 11-05-2025
- PLXS 10-22-2025
- Dividend Yield
- NAMS N/A
- PLXS N/A
- EPS Growth
- NAMS N/A
- PLXS 56.11
- EPS
- NAMS N/A
- PLXS 6.26
- Revenue
- NAMS $35,243,000.00
- PLXS $4,032,966,000.00
- Revenue This Year
- NAMS N/A
- PLXS $10.81
- Revenue Next Year
- NAMS N/A
- PLXS $7.18
- P/E Ratio
- NAMS N/A
- PLXS $22.80
- Revenue Growth
- NAMS 4.91
- PLXS 1.82
- 52 Week Low
- NAMS $14.06
- PLXS $103.43
- 52 Week High
- NAMS $41.47
- PLXS $172.89
- Technical
- Relative Strength Index (RSI)
- NAMS 61.84
- PLXS 53.49
- Support Level
- NAMS $36.59
- PLXS $132.03
- Resistance Level
- NAMS $40.88
- PLXS $142.35
- Average True Range (ATR)
- NAMS 2.59
- PLXS 5.02
- MACD
- NAMS -0.09
- PLXS -0.11
- Stochastic Oscillator
- NAMS 90.44
- PLXS 77.35
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
About PLXS Plexus Corp.
Plexus Corp designs, manufactures, and services complex products in demanding regulatory environments, supporting life-saving medical devices, mission-critical aerospace and defense products, industrial automation systems, and semiconductor capital equipment. Its integrated lifecycle solutions span design and development, supply chain solutions, new product introduction, manufacturing, and sustaining services for market and disruptive companies in the Aerospace/Defense, Healthcare/Life Sciences, and Industrial sectors. The Company operates through three reportable segments: AMER, APAC, and EMEA, with the majority of revenue from the APAC segment.